ABSTRACT
The outbreak of corona virus disease 2019 (COVID-19) in December 2019, caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). It poses a severe threat to global public health. Interleukin-6 (IL-6) was proposed to be associated with the severity of corona virus disease. The present study aimed to explore the role of IL-6 levels with severity in adult CO VID-19 patients. To correlate the serum level of IL-6 with severity of COVID-19 and monitoring of the disease in adult COVID-19 patients.A retrospective study was carried out after obtaining approval from the relevant Ethics Committee. Patients established with COVID-19 infection as shown by positive real-time quantitative PCR test were included. This study was conducted first time in Hadoti region of Jhalawar, Rajasthan. In this study, we have divide patients into three groups common (N=30), severe (N=30) and critical (N=30).The diagnosis and severity classification was based on Clinical Guidance for management of adult Covid-19 patients (Ministry of Health & Family welfare) and WHO interim guideline. The mean concentration of IL-6 were 1.75 +/-0.5 pg/ml, 9.45+/-0.1.5 pg/ml, and 21.55 +/-2.5 pg/ml for the common, severe, and critical groups respectively (P < 0.001 ). Our result shows that serum IL-6 levels increased as disease progress toward critical condition. Serum IL-6 should be included in diagnostic work-up to stratify disease severity. Therefore, full monitoring the severity of COVID-19 and effective early intervention are the fundamental measures for reducing mortality.